Roivant Sciences Ltd. — Company profile
Healthcare · Biotechnology · United Kingdom
Last price 36.91 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 26.66B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Details
| Name | Roivant Sciences Ltd. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 721 |
| Founded | 2014 |
| Ceo | Matthew Gline |
| Country | United Kingdom |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| Isin | BMG762791017 |
| Cusip | G76279101 |
| Cik | 1635088 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Dr. Eric Venker M.D., Pharm.D. | President and Chief Executive Officer of Immunovant |
| Matthew Gline | Chief Executive Officer and Director |
| Dr. Mayukh Sukhatme M.D. | President, Chief Investment Officer and Director |
| Dr. Frank M. Torti M.B.A., M.D. | President and Vant Chair |
| Richard Pulik | Chief Financial Officer |
| Jennifer Humes | Chief Accounting Officer |
| Ian Rosenblum | Chief Information Officer |
| Sam Kaplan | General Counsel |
| Kelly Graff | Head of People |
| Alex Gasner | Executive Vice President of Roivant Health |
Contact
| Address | 50 Broadway, 7th Floor, London, SW1H 0DB, United Kingdom |
| Phone | 44 20 7400 3347 |
| Website | https://roivant.com |